Skip to main content

Advertisement

SpringerLink
Log in

The role of the suspicious renal pharmacist in identifying unusual adverse drug reactions—why this is not a small problem

  • Commentary
  • Published:
International Journal of Clinical Pharmacy Aims and scope Submit manuscript

Abstract

Renal patients have a high incidence of adverse drug reactions due to both pharmacokinetic and pharmacodynamic changes and detecting these adverse drug reactions relies heavily on having a high index of suspicion—which seems to be invoked through experience, whether our own or that of our colleagues. Pharmacists must be vigilant about adverse drug reactions and it is vital that pharmacists continue to teach their colleagues about their experiences identifying less common adverse drug reactions and adverse drug reactions with unusual presentations in addition to simply reporting these adverse drug reactions.

This is a preview of subscription content, log in via an institution to check access.

Access this article

Log in via an institution

Price excludes VAT (USA)
Tax calculation will be finalised during checkout.

Instant access to the full article PDF.

Institutional subscriptions

References

  1. Naranjo CA, Busto U, Sellers EM, Sandor P, Ruiz I, Roberts EA, Janecek E, et al. A method for estimating the probability of adverse drug reactions. Clin Pharacol Ther. 1981;30:239–45.

    Article  CAS  Google Scholar 

  2. Aronson JK, Ferner RE. Joining the DoTS: new approach to classifying adverse drug reactions. BMJ. 2003;327:1222–5.

    Article  CAS  Google Scholar 

  3. Papadopoulos J, Smithburger PL. Common drug interactions leading to adverse drug events in the intensive care unit: management and pharmacokinetic considerations. Crit Care Med. 2010;38(Suppl. 1):S126–35.

    Article  CAS  Google Scholar 

  4. Awdishu L, Mehta RL. The 6R’s of drug induced nephrotoxicity. BMC Nephrol. 2017;18:124–35.

    Article  CAS  Google Scholar 

  5. Wilmer WA, Magro CM. Calciphylaxis: emerging concepts in prevention, diagnosis, and treatment. Semin Dial. 2002;15:172–86.

    Article  Google Scholar 

  6. Hyman BT, Landas SK, Ashman RF, Schelper RL, Robinson RA. Warfarin-related purple toes syndrome and cholesterol microembolization. Am J Med. 1987;82:1233–7.

    Article  CAS  Google Scholar 

  7. Scorza R, Caronni M, Mascagni B, Berruti V, Bazzi S, Micallef E, et al. Effects of long-term cyclic iloprost therapy in systemic sclerosis with Raynaud’s phenomenon. A randomised, controlled study. Clin Exp Rheumatol. 2001;19:503–8.

    CAS  PubMed  Google Scholar 

  8. Cumming K, Hoyle GE, Hutchison JD, Soiza RL. Prevalence, incidence and etiology of hyponatremia in elderly patients with fragility fractures. PLoS ONE. 2014;9:e88272.

    Article  Google Scholar 

  9. William JH, Danziger J. Proton-pump inhibitor-induced hypomagnesemia: current research and proposed mechanisms. World J Nephrol. 2016;5:152–7.

    Article  Google Scholar 

  10. Perazella MA, Markowitz GS. Drug-induced acute interstitial nephritis. Nat Rev Nephrol. 2010;6(461–470):128.

    Google Scholar 

  11. Yarlagadda SG, Perazella MA. Drug-induced crystal nephropathy: an update. Expert Opin Drug Saf. 2008;7:147–58.

    Article  CAS  Google Scholar 

  12. Grill MF, Maganti RK. Neurotoxic effects associated with antibiotic use: management considerations. Br J Clin Pharmacol. 2011;72:381–93.

    Article  CAS  Google Scholar 

  13. Chiu AG, Krowiak EJ, Deeb ZE. Angioedema associated with angiotensin II receptor antagonists: challenging our knowledge of angioedema and its etiology. Laryngoscope. 2001;111:1729–31.

    Article  CAS  Google Scholar 

  14. Riedl MA, Casillas AM. Adverse drug reactions: types and treatment options. Am Fam Physician. 2003;68:1781–90.

    PubMed  Google Scholar 

  15. Bell NH, Gill JR, Bartter FC. On the abnormal calcium absorption in sarcoidosis. Am J Med. 1964;36:500–13.

    Article  CAS  Google Scholar 

  16. Adams JS, Hewison M. Unexpected actions of vitamin D: new perspectives on the regulation of innate and adaptive immunity. Nat Clin Pract Endocrinol Metab. 2008;4:80–90.

    Article  CAS  Google Scholar 

  17. Sathasivam S, Lecky B. Statin induced myopathy. BMJ. 2008;337:1159–62.

    Article  Google Scholar 

  18. Yap YG, Camm AJ. Drug-induced QT prolongation and torsades de pointes. Heart. 2003;89:1363–72.

    Article  CAS  Google Scholar 

  19. Kanjanauthai S, Kanluen T, Chareonthaitawee P. Citalopram induced torsade de pointes, a rare life threatening side effect. Int J Cardiol. 2008;131:e33–4.

    Article  Google Scholar 

  20. Christiansen IS, Pedersen P, Kroigaard M, Mosbech H, Garvey LH. Anaphylaxis to intravenous gentamicin with suspected sensitization through gentamicin-loaded bone cement. J Allergy Clin Immunol Pract. 2016;4:1258–9.

    Article  Google Scholar 

Download references

Acknowledgements

The author would like to thank the nephrologists, Dunedin Hospital, New Zealand for their invaluable teaching and clinical expertise.

Funding

No external funding was received.

Conflicts of interest

The author declares there are no conflicts of interest with respect to the authorship and/or publication of this article.

Author information

Authors and Affiliations

  1. Dunedin Hospital, Dunedin, Otago, New Zealand

    Carolyn Vera Coulter

Authors
  1. Carolyn Vera Coulter
    View author publications

    You can also search for this author in PubMed Google Scholar

Corresponding author

Correspondence to Carolyn Vera Coulter.

Rights and permissions

Reprints and permissions

About this article

Check for updates. Verify currency and authenticity via CrossMark

Cite this article

Coulter, C.V. The role of the suspicious renal pharmacist in identifying unusual adverse drug reactions—why this is not a small problem. Int J Clin Pharm 40, 775–777 (2018). https://doi.org/10.1007/s11096-018-0660-6

Download citation

  • Published:

  • Issue Date:

  • DOI: https://doi.org/10.1007/s11096-018-0660-6

Keywords

Search

Navigation